The National Institute for Health and Care Excellence's questions to Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) about R&D and manufacturing costs for Soliris eculizumab in relation to the drug's price were not foretold by the agency's interim methodology for assessing Orphan drugs. NICE's interim methodology for the Highly Specialized Technology (HST) assessment process outlined six criteria that the evaluation committee would take into account. The evaluation